Navigation Links
eResearchTechnology Reports Second Quarter 2008 Results
Date:8/4/2008

60)

Changes in operating assets and liabilities

exclusive of CCSS acquisition:

Accounts receivable (2,269) (2,622)

Prepaid expenses and other (833) (1,616)

Accounts payable (2,184) (240)

Accrued expenses 382 (1,013)

Income taxes 2,553 348

Deferred revenues (647) 583

Net cash provided by operating activities 12,499 17,978

Investing activities:

Purchases of property and equipment (7,995) (5,239)

Purchases of investments (40,651) -

Proceeds from sales of investments 39,530 2,392

Payments for acquisition - (4,798)

Net cash used in investing activities (9,116) (7,645)

Financing activities:

Repayment of capital lease obligations (1,132) (855)

Proceeds from exercise of stock options 1,462 1,174

Stock option income tax benefit 578 704

Net cash provided by financing activities 908 1,023

Effect of exchange rate changes on cash 108 8

Net increase in cash and cash equivalents 4,399 11,364

Cash and cash equivalents, beginning of period 15,497 38,082

Cash and cash equivalents, end of period $19,896 $49,446


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
2. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
3. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
6. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
7. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
8. eResearchTechnology Reports First Quarter 2008 Results
9. eResearchTechnology Announces Resignation of its CFO
10. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
11. eResearchTechnology Names New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... MORRISTOWN, N.J. , July 28, 2015 /PRNewswire/ ... its second Phase 1 clinical trial with MMI-0100, ... that is being developed for pulmonary disorders characterized ... the United Kingdom , is ... study further evaluating the safety and tolerability of ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 ... today announced its financial results for the second ...  sales grew nearly 300% as compared to the ... first launched," said Roger Jeffs, Ph.D., United Therapeutics, ... Orenitram sales was due to an increase in ...
(Date:7/28/2015)... 2015  Faced with increasing challenges such as ... than symptomatic, the global healthcare industry today is ... of curing or significantly changing the course of ... towards regenerative medicine as a viable alternative. ... human health with the potential to resolve unmet ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... Choices, More Options to Global ... ... Feb. 11,/PRNewswire- FirstCall/ -- DuPont (NYSE: DD ) and Precision ... the market faster. Terms of the agreement were not,disclosed., The ...
... RICHMOND, Va., Feb. 11 A report released,today, commissioned ... savings of approximately $378 billion over the next 20 ... U.S., The econometric study by economist Dr. Robert ... Administration, found that "...generic,versions of the top 12 categories ...
... 11 On Monday, January 28, The ... the first,Volumetric Modulated Arc Therapy (VMAT)* treatment ... To facilitate the treatment, the hospital,used its ... generation,linear accelerator control system., (Logo: ...
Cached Biology Technology:DuPont and Precision BioSciences Collaborate to Accelerate Crop Product Development 2Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 2Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 3Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 4Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 5Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital 2
(Date:7/2/2015)... , June 25, 2015 ... the addition of the "Natural Language Processing ... (Recognition, IVR, OCR, Pattern & Image Recognition) - ... offering. The key vendors occupying the ... IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... evolution works by reversing the process, reconstructing a 530-million-year-old ... genes that descended from the archaic gene. , "It ... evolution has occurred and is occurring, and thus makes ... and co-chairman of human genetics at the University of ...
... important new paper forthcoming in the June issue of ... University) argues against the widely held theory that the ... a large, replicating molecule such as RNA. Instead, ... a "stupendously improbable accident," presenting the more plausible idea ...
... of Warwick has found that sleep deprivation is associated ... obese for both children and adults. , Early results ... University of Warwick's Warwick Medical School were presented to ... the University of Warwick. , The research reviewed current ...
Cached Biology News:Scientists reverse evolution 2Scientists reverse evolution 3Scientists reverse evolution 4Scientists reverse evolution 5Sleep deprivation doubles risks of obesity in both children and adults 2
... Detergent Clean-up Micro Kit provides a fast and ... Triton X-100 and other detergents from small samples ... Norgens patented protein resin as an ion exchanger. ... g of either acidic or basic protein.A complete ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... cells form from a hematopoietic stem cells ... to the bone surface and lowering the ... around 4.5. The bone mineral is then ... and function is controlled primarily by Macrophage ...
Values of steady state parameters for enzyme activities are determined....
Biology Products: